Duvelisib with Docetaxel for Patients with Anti-PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Duvelisib联合多西他赛治疗抗PD-1耐药、复发或转移性头颈部鳞状细胞癌患者
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-2262
Hanna, Glenn J; Oakley, L B; Shi, R; ONeill, A; Shin, K Y; Scarfo, N; Sehgal, K; Dennis, M J; Quinn, N; Jo, V Y; Wong, K; Shvyrkova, A; Kushnarev, V; Shanthappa, B U; Tkachuk, A; Kryukov, K; Sarachakov, A; Svekolkin, V; Lennerz, J; Waters, S; Haddad, R I